Centessa (CNTA) Pharmaceuticals announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, as CEO and member of the Board, effective January 1, 2026. Dr. Accardi will succeed Saurabh Saha MD PhD, who will step down from his position as CEO and a member of the Board, effective January 1, 2026. Dr. Saha will be appointed advisor to the CEO.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa assumed with an Outperform at Oppenheimer
- Centessa price target raised to $42 from $33 at B. Riley
- Centessa Pharmaceuticals Amends Sales Agreement for Flexibility
- Centessa price target raised to $43 from $28 at Guggenheim
- Centessa Pharmaceuticals Announces Underwriting Agreement for ADS Offering